Sara Tolaney, MD, Associate Director, Susan F. Smith Center for Womens Cancers, Director Clinical Trials, Breast Oncology, Associate Professor of Medicine, Harvard Medical School provides an overview of the SOPHIA trial, a phase III of chemotherapy plus margetuximab or trastuzumab in HER+ metastatic breast cancer after pertuzumab with 1-3 prior lines of treatment.
SOPHIA Trial Outcomes
